ACB:NSD-Aurora Cannabis Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 6.01

Change

-0.02 (-0.33)%

Market Cap

USD 1.22B

Volume

8.51M

Avg Analyst Target

USD 8.15 (+35.68%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories, including valves, screens, etc.; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and ROAR Sports. Aurora Cannabis Inc. is headquartered in Edmonton, Canada. Address: Edmonton International Airport, Edmonton, AB, Canada, T9E 0V6

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CGC Canopy Growth Corporation

+0.65 (+4.81%)

USD5.33B N/A N/A
TLRY Tilray Inc

+0.41 (+3.65%)

USD5.04B N/A N/A
PCRX Pacira BioSciences Inc

+0.44 (+0.77%)

USD2.54B 14.84 23.27
CRON Cronos Group Inc

+0.23 (+4.06%)

USD2.13B 37.00 N/A
IRWD Ironwood Pharmaceuticals Inc

-0.06 (-0.47%)

USD2.06B 4.05 9.52
ORGO Organogenesis Holdings Inc

-0.58 (-3.48%)

USD2.03B 28.13 23.24
DVAX Dynavax Technologies Corporati..

+3.93 (+26.45%)

USD1.71B N/A 86.82

ETFs Containing ACB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.55% 33% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.55% 33% F 14% F
Trailing 12 Months  
Capital Gain 16.25% 62% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.25% 62% D- 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 105.04% 97% A+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.04% 97% A+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 296.09% 3% F 5% F
Risk Adjusted Return 35.48% 77% C+ 51% F
Market Capitalization 1.22B 86% B 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.15 23% F 22% F
Price/Book Ratio 0.76 97% A+ 95% A
Price / Cash Flow Ratio -3.61 45% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -80.33% 38% F 21% F
Return on Invested Capital -10.61% 65% D 34% F
Return on Assets -7.20% 58% F 31% F
Debt to Equity Ratio 13.87% 60% D- 66% D
Technical Ratios  
Short Ratio 9.02 23% F 14% F
Short Percent 18.31% 5% F 8% F
Beta 3.24 7% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector